

Valens™ Vaccine Adjuvants and Biologics

Valens™ T4AH: TLR4 Agonist & Aluminum Hydroxide Adjuvant System



Valens™ T4AH adjuvant system is an adjuvant system combining Inimmune's novel fully synthetic TLR4 agonist INI-2002 with aluminum adjuvants from SPI Pharma. Valens™ T4AH offer advantages over current clinical adjuvants including improved availability, stability, and production sustainability. INI-2002 alone offers greatly improved stability compared to current clinical TLR4 adjuvants.

In July 2024, SPI Pharma and Inimmune Corp announced a partnership to develop and commercialize this innovative system.

Efficacy in Pre-Clinical Models

- T4AH demonstrates comparable or improved immunogenicity compared to current clinical TLR4 + Alum adjuvant combinations.
- Strong antibody response; Th1 T cell responses can be generated depending on the antigen that is being investigated.
- Our research demonstrates that T4AH is particularly effective in increasing immune responses to poorly immunogenic antigens.

cGMP Manufacturing

- INI-2002 has been manufactured under cGMP conditions.
- SPI Pharma manufactures Alum adjuvants under cGMP conditions.
- T4AH cGMP manufacturing is in progress.

SPI Pharma, as the commercial partner, can assist you with Inimmune's expertise to help develop vaccines readily and easily from our T4AH platform. Please contact SPI Pharma to discuss your needs further, including T4AH samples and relevant data.

www.spipharma.com • salesinfo@spipharma.com



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

8/2025
© 2025 SPI Pharma